Product Description
TAK-105 will be used to help treat people with nausea and vomiting
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TAK-105-1001 | P1 |
Completed |
Healthy Volunteers |
2023-06-20 |